BiotechTube

TNX-102 SL 5.6 mg

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PTSD

Conditions

PTSD

Trial Timeline

Apr 19, 2018 → Sep 30, 2019

NCT ID
NCT03508700

About TNX-102 SL 5.6 mg

TNX-102 SL 5.6 mg is a phase 3 stage product being developed by Tonix Pharmaceuticals for PTSD. The current trial status is completed. This product is registered under clinical trial identifier NCT03508700. Target conditions include PTSD.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03508700Phase 3Completed

Competing Products

11 competing products in PTSD

See all competitors
ProductCompanyStageHype Score
SYN117 (nepicastat) + Placebo comparatorJohnson & JohnsonPhase 2
52
Quetiapine + PlaceboJohnson & JohnsonApproved
85
Lu AG06466 + PlaceboLundbeckPhase 1
30
Mifepristone 1200 mg daily + PlaceboCorcept TherapeuticsPhase 2
47
TNX-102 SLTonix PharmaceuticalsPhase 2
44
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SL + Placebo SL TabletTonix PharmaceuticalsPhase 3
69
TNX-102 SL + PlaceboTonix PharmaceuticalsPhase 2
44
TNX-102 SL + Placebo SL TabletsTonix PharmaceuticalsPhase 3
69
TNX-102 SLTonix PharmaceuticalsPhase 3
69
Ganaxolone + PlaceboBrain BiotechPhase 2
44

Other Products from Tonix Pharmaceuticals

TNX-102 SLPhase 3
69
TNX-102 SL Tablet, 2.8 mg + Placebo SL TabletPhase 3
69
TNX-102 SL Tablet, 2.8mg + Placebo SL TabletPhase 3
69
TNX-102 SL + Placebo SL TabletPhase 3
69
TNX-102 SL Tablet 2.8 mgPhase 3
69